dbDNA™: An advanced platform for genetic medicines

•Touchlight has developed dbDNA for the scalable generation of high-quality GMP DNA free of bacterial sequences.•dbDNA has been proven both an enabling technology for the production of viral vectors and mRNA, and as a direct therapeutic.•Industrial-scale GMP manufacturing facilities are currently in...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2022-02, Vol.27 (2), p.374-377
Main Authors: Adie, Tom, Orefo, Ifey, Kysh, Daniel, Kondas, Katalin, Thapa, Shyam, Extance, Jon, Duncan, Tommy, Rothwell, Paul J.
Format: Article
Language:English
Subjects:
Biotech
dbDNA
DNA
Genetic medicine
GMP
Protelomerase
Touchlight Genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Touchlight has developed dbDNA for the scalable generation of high-quality GMP DNA free of bacterial sequences.•dbDNA has been proven both an enabling technology for the production of viral vectors and mRNA, and as a direct therapeutic.•Industrial-scale GMP manufacturing facilities are currently in operation in the UK and Spain.•Touchlight is therefore uniquely positioned to enable scale up of advanced therapies and DNA therapeutics to industrial quantities.•dbDNA is made using a synthetic route, enabling a simpler regulatory pathway than that applied to conventional biologic processes. The supply of plasmid DNA has become a major bottle neck in the ever-expanding genetic medicine sector. Therefore, the development of new, scalable, faster DNA production technologies is vital for this sector going forward.
ISSN:1359-6446
1878-5832
DOI:10.1016/j.drudis.2021.09.018